Welcome to our dedicated page for Journey Medical SEC filings (Ticker: DERM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Journey Medical Corporation filings document the regulatory record of a Nasdaq-listed commercial-stage dermatology pharmaceutical company. The company’s Form 8-K reports cover financial results, corporate updates, Emrosi commercialization disclosures, pharmacy benefit coverage developments, and material agreements tied to its capital and operating structure.
DERM filings also include proxy materials for annual stockholder matters, including director elections and auditor ratification. Capital-structure disclosures include a term loan credit agreement amendment, an at-the-market common stock sales agreement under a Form S-3 registration statement, Nasdaq Capital Market common stock registration details, and emerging growth company status.
Wasatch Advisors filed Amendment No. 3 to a Schedule 13G reporting beneficial ownership of 2,858,930 shares of Journey Medical Corp common stock, representing 13.3% of the class. The shares are held with sole power to dispose and sole voting power over 2,664,647 shares, with no shared voting or dispositive authority.
Toledano Miranda Jayne reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Toledano Miranda Jayne received a grant of 50,000 shares of common stock in the form of restricted stock units on July 1, 2026 under the company’s 2015 Stock Plan. These RSUs vest in three annual installments: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030, and 16,667 shares on July 1, 2031.
Following this award, Toledano directly holds 168,618 shares of Journey Medical common stock, including restricted stock units that vest over various time periods. The grant reflects equity-based compensation rather than an open-market purchase.
Smith Justin Adam reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Justin Adam Smith received a grant of 50,000 restricted stock units as equity compensation. The award was granted on July 1, 2026 under Journey Medical Corp's 2015 Stock Plan, as amended. These restricted stock units vest over a long-term schedule: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030 and 16,667 shares on July 1, 2031, tying the director’s compensation to the company’s future performance. Following this grant, Smith directly holds a total of 231,618 shares and restricted stock units, which vest over various time periods.
Herskowitz Neil reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Neil Herskowitz received a grant of 50,000 restricted stock units (RSUs) of common stock as equity compensation. The grant was made on July 1, 2026 under the company’s 2015 Stock Plan and will vest over several years.
The RSUs vest in three tranches: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030, and 16,667 shares on July 1, 2031, if applicable conditions are met. After this award, Herskowitz’s direct holdings, including RSUs that vest over time, total 168,618 shares.
Toledano Miranda Jayne reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Miranda Jayne Toledano received an equity award of 10,000 shares of common stock in the form of restricted stock units. The grant was made on June 25, 2026 under the company’s 2015 Stock Plan, as amended.
The 10,000 restricted stock units are scheduled to vest in full on June 25, 2027, increasing her time-based incentive to remain aligned with shareholders. After this grant, Toledano’s direct holdings, including other restricted stock units that vest over various periods, total 118,618 shares of Journey Medical common stock.
Smith Justin Adam reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Justin Adam Smith received a grant of 10,000 shares of common stock as restricted stock units on June 25, 2026. These units were issued under the company’s 2015 Stock Plan and will vest as 10,000 shares on June 25, 2027.
After this equity award, Smith’s direct holdings total 181,618 shares, including restricted stock units that vest over various time periods. This is a compensation-related equity grant rather than an open-market share purchase or sale.
Herskowitz Neil reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Neil Herskowitz received a grant of 10,000 restricted stock units as equity compensation. The award was made under the company’s 2015 Stock Plan and will vest in full on June 25, 2027. Following this grant, Herskowitz’s direct holdings total 118,618 shares, including restricted stock units that vest over various periods.
Pearce Michael Cooper reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Michael Cooper received a grant of 10,000 restricted stock units (RSUs). The award, granted on June 25, 2026 under the company’s 2015 Stock Plan, will vest in full as 10,000 shares on June 25, 2027. After this grant, Cooper directly holds 67,173 shares of Journey Medical common stock, including RSUs that vest over various time periods.
ROSENWALD LINDSAY A MD reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Lindsay A. Rosenwald, M.D. reported an equity compensation award rather than an open-market trade. On June 25, 2026, he was granted 10,000 restricted stock units that are scheduled to vest as 10,000 shares on June 25, 2027.
After this award, his direct holdings of common stock, including restricted stock units that vest over various periods, total 221,146 shares. A separate entry shows 176,470 shares held indirectly through a limited liability company over which he, as managing member, is deemed to have voting and investment power.
Journey Medical Corporation reported the results of its 2026 annual stockholder meeting held via virtual platform. Stockholders representing 16,145,526 shares of common stock and 6,000,000 shares of Class A common stock, together 81% of the 27,346,466 shares entitled to vote, were present, establishing a quorum.
All six director nominees were elected, each receiving over 31.7 million votes in favor, with broker non-votes of 6,515,971 for each nominee. Stockholders also ratified KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 39,374,407 votes for, 50,168 against, and 202,042 abstentions.